Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies.

Key Takeaways

  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.
Dallas, TX - July 12, 2023 - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics. The report, The RNA Revolution: Unleashing the Therapeutic Potential of RNAi, highlights the potential of RNA therapeutics and companies leveraging RNAi technologies are in particular focus as we believe this will be a meaningful area of development.
Other companies highlighted in the report represent various areas of RNA therapeutics, namely mRNA and aptamers. This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in RNA therapeutics, providing valuable insights for investors and companies.
For further information or to obtain a FREE copy of the full report, please contact our research team - alamgir@stonegateinc.com 

About Stonegate Healthcare
The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.

Key Takeaways

  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.

Media Gallery

Related Bios

Shiv Kapoor
Managing Partner at Stonegate Healthcare Partners
Shiv has a BA in Biochemistry UC Berkeley, and an MBA from the University of Chicago Booth School of Business. He ran the Smith Barney Biotech fund at Citigroup and started Sellside Biotech practices at Montgomery & Co. and Morgan Joseph. In 2008 he was rated among the top three biotechnology analysts by Forbes in the US. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. In the past decade, Shiv had leading roles as an investor relations and strategy executive at Spectrum pharmaceuticals. He is the founder and CEO of BioRamon Pharmaceuticals, a biopharmaceutical company involved in the discovery and research of oncology medicine.
View Full Bio>>
Alamgir Singh Kandhari
Research Analyst at Stonegate Healthcare Partners
Alamgir has a BA in Biology from the University of California Santa Cruz and a Master of Biotechnology from San Jose State University. Prior to his role at Stonegate Alamgir ran GMP production processes at BioMarin Pharmaceuticals, led a project at an immune-oncology start-up to target leukemia stem cells in AML, and researched aberrant pre-mRNA splicing leading to genetic diseases in the Sanford Lab at UCSC. He has experience in scientific writing, planning, presenting, GMP production, and project management.
View Full Bio>>

Contacts

Shiv Kapoor
Shiv@stonegateinc.com
Stonegate Healthcare Partners
info@stonegateinc.com
(214) 987-4121
General